An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g. Pegasys/peginterferon alfa-2a) and ribavirin. Data will be collected from each patient for the duration of their treatment and for up to 6 months thereafter.
Correlation between baseline patient characteristics and safety related dose reductions/treatment discontinuations of the long-acting interferon or ribavirin [ Time Frame: 4 years ]
Correlation between safety related dose reductions/treatment discontinuations and sustained virological response (SVR: defined as HCV RNA <50 IU/mL at 24 weeks after completion of treatment) [ Time Frame: 4 years ]
Secondary Outcome Measures
Correlation of on-treatment factors and dose reduction/treatment discontinuation [ Time Frame: 4 years ]
Correlation between degree of dose reductions/treatment interruptions (percentage of actual exposure/treatment administrations in relation to target exposure) and SVR [ Time Frame: 4 years ]
Comparison of on-treatment virological response (rapid virological response, early virological response) in treatment-naïve and treatment experienced patients [ Time Frame: 4 years ]
Safety: Incidence of adverse events [ Time Frame: 4 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with chronic hepatitis C receiving a long-acting interferon plus ribavirin
Adult patients (according to local legislation)
Chronic hepatitis C
Treatment with long-acting interferon plus ribavirin
Quantifiable HCV RNA before initiation of treatment
No contra-indications to long-acting interferon and ribavirin therapy as detailed in the label